Pulmonary involvement in Fabry disease: Overview and perspectives

European Journal of Internal Medicine

Volumn 24, Issue 8, 2013, Pages 707-713

  Franzen, Daniel ^a   Krayenbuehl, Pierre A ^a   Lidove, Olivier ^b   Aubert, John David ^c   Barbey, Frederic ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bronchiolar; Fabry disease; Lung; Obstructive; Pulmonary; Respiratory

Indexed keywords

ALPHA GALACTOSIDASE; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; GLYCOSPHINGOLIPID; RECOMBINANT ALPHA GALACTOSIDASE; UNCLASSIFIED DRUG;

AIRWAY; ARTICLE; BRONCHUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; ELECTRON MICROSCOPY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EXERCISE TOLERANCE; FABRY DISEASE; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; LYSOSOME STORAGE DISEASE; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDERED BREATHING; SMALL AIRWAY DISEASE; SMOKING; SPIROMETRY; SYMPTOM; TREATMENT OUTCOME; X CHROMOSOME LINKED DISORDER;

BRONCHIOLAR; FABRY DISEASE; LUNG; OBSTRUCTIVE; PULMONARY; RESPIRATORY;

BRONCHIOLES; FABRY DISEASE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERPLASIA; LUNG DISEASES, OBSTRUCTIVE; MYOCYTES, SMOOTH MUSCLE;

EID: 84889674531     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.05.003     Document Type: Review

References (56)

1. Y.A. Zarate, and R.J. Hopkin Lysosomal storage disease 3. Fabry's disease Lancet 372 2008 1427 1435
2. J. Fabry Zur Klinik und Aetiologie des Angiokeratoma Arch Dermatol 123 1916 294 307
3. J. Fabry Weiterer Beitrag zur Klinik des Angiokeratoma Naeviforme (Naevus angiokeratosus) Dermatol Wochenschr 90 1930 339 341
4. C.C. Sweeley, and B. Klionsky Glycolipid lipidosis: Fabry's disease J.B. Stanbury, J.B. Wyngaarden, D.S. Fredrickson, The metabolic basis of inherited diseases 1966 McGraw-Hill Book Co New York
5. J.D. Bagdade, F. Parker, P.O. Ways, T.E. Morgan, D. Lagunoff, and S. Eidelman Fabry's disease: a correlative clinical, morphologic and biochemical study Lab Invest 18 1968 681 688
6. B.R. Line, J.A. Barranger, R.O. Brady, and R.G. Crystal Chronic airflow obstruction in Fabry's disease Am J Med 68 1980 898 905
7. P. Smith, D. Heath, B. Rodgers, and T. Helliwell Pulmonary vasculature in Fabry's disease Histopathology 19 1991 567 569
8. J.T. Abe, A.H. Cohen, and W.R. Wilcox Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage J Inherit Metab Dis 31 2008 S369 S374
9. M.M. Kelly, R. Leigh, R. McKenzie, D. Kamada, E.H. Ramsdale, and F.E. Hargreave Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease Thorax 55 2000 720 721
10. E.E. Bartimmo Jr., M. Guisan, and K.M. Moser Pulmonary involvement in Fabry's disease: a reappraisal follow-up of a San Diego kindred and review of literature Am J Med 53 1972 755 764
11. J.W. Koskenvuo, I.M. Kantola, P. Nuutila, J. Knuuti, R. Parkkola, and I. Mononen Cardiopulmonary involvement in Fabry's disease Acta Cardiol 65 2010 185 192
12. A. Mehta, J.T. Clarke, R. Giugliani, P. Elliott, A. Linhart, and M. Beck Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey J Med Genet 46 2009 548 552
13. W. Kim, R.E. Pyeritz, B.A. Bernhardt, M. Casey, and H.I. Litt Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy Am J Med Genet A 143 2007 377 381
14. K. Kariman, W.V. Singletary Jr., and H.O. Sieker Pulmonary involvement in Fabry's disease Am J Med 64 1978 911 912
15. L.K. Brown, A. Miller, A. Bhuptani, M.F. Sloane, M.I. Zimmerman, and G. Schilero Pulmonary involvement in Fabry disease Am J Respir Crit Care Med 155 1997 1004 1010
16. G. Bierer, N. Kamangar, D. Balfe, W.R. Wilcox, and Z. Mosenifar Cardiopulmonary exercise testing in Fabry disease Respiration 72 2005 504 511
17. F. Barbey, U. Widmer, T. Brack, B. Vogt, and J. Aubert Spirometric abnormalities in patients with Fabry disease and effect of enzyme replacement therapy Acta Paediatr Suppl 447 2005 105
18. J.D. Aubert, and F. Barbey Pulmonary involvement in Fabry disease A. Mehta, M. Beck, G. Sunder-Plassmann, Fabry disease: perspectives from 5 years of FOS 2006 Oxford PharmaGenesis Oxford [Chapter 27]
19. G. Bierer, D. Balfe, W.R. Wilcox, and Z. Mosenifar Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease J Inherit Metab Dis 29 2006 572 579
20. S. Magage, J.C. Lubanda, Z. Susa, J. Bultas, D. Karetová, and R. Dobrovolný Natural history of the respiratory involvement in Anderson-Fabry disease J Inherit Metab Dis 30 2007 790 799
21. N.B. Pride, and P.T. Macklem Lung mechanics in disease P.T. Macklem, J. Mead, Handbook of physiology. The respiratory system. Mechanics of breathing. Section 3, Vol. III, part 2 1986 Bethesda American Physiological Society 659 692
22. American Thoracic Society Lung function testing: Selection of reference values and interpretative strategies Am Rev Respir Dis 144 1991 1202 1218
23. R. Pellegrino, G. Viegi, V. Brusasco, R.O. Crapo, F. Burgos, and R. Casaburi Interpretative strategies for lung function tests Eur Respir J 26 2005 948 968
24. R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, S.S. Hurd GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Am J Respir Crit Care Med 163 2001 1256 1276
25. B.R. Celli, W. MacNee committe members Standard for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
26. B.R. Celli, R.J. Halbert, S. Isonaka, and B. Schau Population impact of different definition of airway obstruction Eur Respir J 22 2003 268 273
27. P.O. Bridevaux, N.M. Probst-Hensch, C. Schindler, I. Curjuric, D. Felber Dietrich, and O. Braendli Prevalence of airflow obstruction in smokers and never-smokers in Switzerland Eur Respir J 36 2010 1259 1269
28. F.A. Mohamed Hoesein, P. Zanen, and J.W. Lammers Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review Respir Med 105 2011 907 915
29. A.S. Buist, M.A. McBurnie, W.M. Vollmer on behalf of the BOLD Collaborative Research Group International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study Lancet 370 2007 741 749
30. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
31. R.Y. Wang, A. Lelis, J. Mirocha, and W.R. Wilcox Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life Genet Med 9 2007 34 45
32. P.N. Lee, and J.S. Fry Systematic review of the evidence relating FEV1 decline to giving up smoking BMC Med 8 2010 84
33. X. Xu, D.W. Dockery, J.H. Ware, F.E. Speizer, and B.G. Ferris Jr. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment Am Rev Respir Dis 146 1992 1345 1348
34. C. Tantucci, and D. Modina Lung function decline in COPD Int J Chron Obstruct Pulmon Dis 7 2012 95 99
35. T. Heare, N.J. Alp, D.A. Priestman, A.B. Kulkarni, P. Qasba, and T.D. Butters Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment J Inherit Metab Dis 30 2007 79 87
36. F. Barbey, N. Brakch, A. Linhart, N. Rosenblatt-Velin, X. Jeanrenaud, and S. Qanadli Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition Arterioscler Thromb Vasc Biol 26 2006 839 844
37. N. Brakch, O. Dormond, S. Bekri, D. Golshayan, M. Correvon, and L. Mazzolai Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease Eur Heart J 31 2010 67 76
38. J.E. Hansen, X.G. Sun, and K. Wasserman Discriminating measures and normal values for expiratory obstruction Chest 129 2006 369 377
39. L. Marazzini, G. Cavigioli, B. Mastropasqua, and A. Pelucchi FEV1 decline in asymptomatic young adults: relationships with some tests of small airways function Eur Respir J 2 1989 817 821
40. A. Devakonda, S. Raoof, A. Sung, W.D. Travis, and D. Naidich Bronchiolar disorders: a clinical-radiological diagnostic algorithm Chest 137 2010 938 951
41. N. Macintyre, R.O. Crapo, G. Viegi, D.C. Johnson, C.P. van der Grinten, and V. Brusasco Standardisation of the single-breath determination of carbon monoxide uptake in the lung Eur Respir J 26 2005 720 735
42. R.O. Crapo, R.L. Jensen, and J.S. Wanger Single-breath carbon monoxide diffusing capacity Clin Chest Med 22 2001 637 649
43. T. Duning, M. Deppe, S. Keller, H. Schiffbauer, J. Stypmann, and M. Böntert Excessive daytime sleepiness is a common symptom in fabry disease Case Rep Neurol 1 2009 33 40
44. R.J. Desnick, R. Brady, J. Barranger, A.J. Collins, D.P. Germain, and M. Goldman Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 138 2003 338 346
45. J. Robbins, S. Redline, A. Ervin, J.A. Walsleben, J. Ding, and F.J. Nieto Associations of sleep-disordered breathing and cerebral changes on MRI J Clin Sleep Med 1 2005 159 165
46. A. Fellgiebel, M.J. Muller, and L. Ginsberg CNS manifestations of Fabry's disease Lancet Neurol 5 2006 791 795
47. K.E. Crutchfield, N.J. Patronas, J.M. Dambrosia, K.P. Frei, T.K. Banerjee, and N.W. Barton Quantitative analysis of cerebral vasculopathy in patients with Fabry disease Neurology 50 1998 1746 1749
48. T. Brack, W. Randerath, and K.E. Bloch Cheyne-Stokes respiration in patients with heart failure: prevalence, causes, consequences and treatments Respiration 83 2012 165 176
49. C. Chimenti, L. Padua, C. Pazzaglia, E. Morgante, C. Centurion, and D. Antuzzi Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study Hum Pathol 43 2012 1444 1452
50. C.A. Mapes, R.L. Anderson, C.C. Sweeley, R.J. Desnick, and W. Krivit Enzyme replacement in Fabry's disease, an inborn error of metabolism Science 169 1970 987 989
51. R.O. Brady, J.F. Tallman, W.G. Johnson, A.E. Gal, W.R. Leahy, and J.M. Quirk Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease N Engl J Med 289 1973 9 14
52. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, and S. Waldek International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease N Engl J Med 345 2001 9 16
53. R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, and T. Weibel Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2001 2743 2749
54. A. Mehta, M. Beck, P. Elliott, R. Giugliani, A. Linhart, and G. Sunder-Plassmann Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data Lancet 374 2009 1986 1996
55. C. Whybra, C. Kampmann, F. Krummenauer, M. Ries, E. Mengel, and E. Miebach The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy Clin Genet 65 2004 299 307
56. E.H. Giannini, A.B. Mehta, M.J. Hilz, M. Beck, D.G. Bichet, and R.O. Brady A validated disease severity scoring system for Fabry disease Mol Genet Metab 99 2010 283 290